TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL [SIN16425P]

Product Info

TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL

[SIN16425P]

Indication

2. INDICATIONS AND USAGE

TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

Dosing

3. DOSAGE AND ADMINISTRATION

3.1. Important Use Information
Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite SN-38.

3.2. Recommended Dosage
The recommended dosage of TRODELVY is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until disease progression or unacceptable toxicity. Do not administer TRODELVY at doses greater than 10 mg/kg.

Administer TRODELVY as an intravenous infusion only. Do not administer as an intravenous push or bolus.

First infusion: Administer infusion over 3 hours. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions [see Warning and Precautions (5.3) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].

Subsequent infusions: Administer infusion over 1 to 2 hours if prior infusions were tolerated. Observe patients during the infusion and for at least 30 minutes after infusion.

Premedication
Prior to each dose of TRODELVY, premedication for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV) is recommended.

• Premedicate with antipyretics, H1 and H2 blockers prior to infusion, and corticosteroids may be used for patients who had prior infusion reactions.

• Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK₁ receptor antagonist, as well as other drugs as indicated).

Prophylaxis for Neutropenia
Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is recommended starting in the first cycle for all patients at increased risk of febrile neutropenia [see Warnings and Precautions (5.1) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].

3.3. Dose Modifications for Adverse Reactions
Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of TRODELVY as described in Tables 1 and 2. Do not re-escalate the TRODELVY dose after a dose reduction for adverse reactions has been made.

The recommended dosage modifications for adverse reactions are provided in Table 2.

3.4. Preparation and Administration
Reconstitution

• TRODELVY is a hazardous drug.

• Follow applicable special handling and disposal procedures.

• Calculate the required dose (mg) of TRODELVY based on the patient’s current body weight [see Dosage and Administration (3.2)].

• Using a sterile syringe, slowly inject 20 mL of 0.9% Sodium Chloride Injection, into each 180 mg TRODELVY vial. Each vial contains overfill to compensate for liquid loss during preparation and after reconstitution, the total resulting volume delivers a concentration of 10 mg/mL.

• Gently swirl vials and allow to dissolve for up to 15 minutes. Do not shake. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be free of visible particulates, clear and yellow. Do not use the reconstituted solution if it is cloudy or discolored.

• Use immediately to prepare a diluted TRODELVY infusion solution.

Dilution

• Calculate the required amount of the reconstituted TRODELVY solution needed to obtain the appropriate dose according to the patient’s body weight.

• Determine the final volume of the infusion solution to deliver the appropriate dose at a TRODELVY concentration range of 1.1 mg/mL to 3.4 mg/mL (the total volume should not exceed 500 mL for patients weighing less than or equal to 170 kg). For patients whose body weight exceeds 170 kg, divide the total calculated dose between two 500 mL infusion bags. The 2 bags should be infused sequentially over the total calculated infusion time of TRODELVY in order to deliver the full dose.

• Use 0.9% Sodium Chloride Injection, only since the stability of the reconstituted TRODELVY solution has not been determined with other infusion-based solutions. Use a polyvinyl chloride, polypropylene/polyethylene or ethylene vinyl acetate infusion bag.

• Withdraw and discard the volume of 0.9% Sodium Chloride Injection, from the final infusion bag that is necessary to achieve the indicated TRODELVY concentration following the addition of the calculated amount of reconstituted TRODELVY solution.

• Withdraw the calculated amount of the reconstituted TRODELVY solution from the vial(s) using a syringe. Discard any unused portion remaining in the vial(s).

• To minimize foaming, slowly inject the calculated amount of reconstituted TRODELVY solution into the infusion bag. Do not shake the contents.

• If not used immediately, the infusion bag containing TRODELVY solution can be stored refrigerated at 2°C to 8°C for up to 24 hours protected from light. After refrigeration, administer diluted solution at room temperature up to 25°C within 8 hours (including infusion time).

Do Not Freeze or Shake.

Administration

• Administer TRODELVY as an intravenous infusion. Protect infusion bag from light. The infusion bag should be covered during administration to the patient until dosing is complete. It is not necessary to cover the infusion tubing or to use light-protective tubing during the infusion.

• An infusion pump may be used.

• Do not mix TRODELVY, or administer as an infusion, with other medicinal products.

• Upon completion of the infusion, flush the intravenous line with 20 mL 0.9% Sodium Chloride Injection.

Contraindications

4. CONTRAINDICATIONS

TRODELVY is contraindicated in patients who have experienced a severe hypersensitivity reaction to TRODELVY [see Warnings and Precautions (5.3) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].